Blopress

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Blopress was produced by Takeda.

Takeda CEO admits to Blopress mis-marketing

Hasegawa told the Wall Street Journal that the company had used a graph in promotional literature indicating Blopress (candesartan cilexetil) was more effective than rival blood pressure drug Norvasc (amlodipine) from ... Blopress - also sold as Atacand -

Takeda rides out Actos decline as fiscal 2012 sales rise

steep decline for antihypertensive Blopress (candesartan), also on generic competition, which ended the year down 22 per cent to 169bn yen. ... The drug's US launch is due in the summer. Azilva also contributed to Takeda's domestic sales growth on the

Country report: The healthcare market in Japan

Aricept. donepezil. Eisai. Alzheimer's disease. 2. Blopress. candesartan. Takeda. Hypertension. 3.

EU approval for Takeda's once-daily hypertension drug Edarbi

Takeda's own candesartan cilexetil (marketed as Amias and Blopress in Europe), which made $2.8bn last year.

A rush for sweet success

DysportTM (Medicis). Glabellar lines. US. Candesartan cilexetil/hydrochlorothiazide. Blopress Plus (Takeda). Essential hypertension.

1 2 3 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

COVID-19 Updates and Daily News

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....